Compare Shopify Inc. (SHOP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shopify Inc. vs TG Therapeutics Inc — how do they compare? Shopify Inc. trades at $170.62 (market cap $211.73B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Shopify Inc. is far larger — about 25.9× TG Therapeutics Inc's market cap, and Shopify Inc. is more actively traded (7,146,651 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Shopify Inc. for 78 Days and TG Therapeutics Inc for 16 Days on average.
| SHOP | TGTX | |
|---|---|---|
Market Cap | $211.73B | $8.16B |
Volume | 7,146,651 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $179.01 | $59.06 |
52-Week Low | $95.40 | $26.94 |
Typical Hold Time | 78 Days | 16 Days |
Enterprise Value | $206.96B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shopify (SHOP) trades at $170.85, up 2.96% today, showing strong momentum near its 52-week high. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, Shopify demonstrates robust revenue growth from $5.6B in 2022 to $11.6B in 2025, with net income turning positive and reaching $1.23B. Recent earnings show mixed results with one miss and two beats in the last three quarters.
Shopify's outlook remains positive with accelerating merchant solutions growth and AI innovations, though elevated valuation metrics (P/E of 111.19) present risk. Analyst consensus is strongly bullish with 67% buy ratings and $168.63 price target. Key risks include competitive pressures from Amazon and valuation sensitivity to growth expectations.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
